CCCC - C4 Therapeutics, Inc.
IEX Last Trade
3.78
0.020 0.529%
Share volume: 29,138
Last Updated: Fri 27 Dec 2024 06:30:16 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.40%
PREVIOUS CLOSE
CHG
CHG%
$3.76
0.02
0.53%
Fundamental analysis
9%
Profitability
0%
Dept financing
9%
Liquidity
75%
Performance
2%
Performance
5 Days
-4.68%
1 Month
-7.64%
3 Months
-37.88%
6 Months
-16.41%
1 Year
-26.57%
2 Year
-36.35%
Key data
Stock price
$3.78
DAY RANGE
$3.74 - $4.04
52 WEEK RANGE
$3.96 - $11.88
52 WEEK CHANGE
-$35.82
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: Andrew J. Hirsch
Region: US
Website: c4therapeutics.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: c4therapeutics.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting multiple myeloma and non-Hodgkin lymphomas. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Recent news